134,566 Shares in Biogen Inc. $BIIB Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the fourth quarter, Holdings Channel reports. The institutional investor bought 134,566 shares of the biotechnology company’s stock, valued at approximately $23,682,000. Biogen accounts for approximately 0.5% of Y Intercept Hong Kong Ltd’s investment portfolio, making the stock its 11th largest position.

A number of other hedge funds have also made changes to their positions in BIIB. WPG Advisers LLC increased its position in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares in the last quarter. Accredited Wealth Management LLC increased its position in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares in the last quarter. First Horizon Corp acquired a new stake in shares of Biogen during the 4th quarter worth about $30,000. WFA of San Diego LLC acquired a new stake in shares of Biogen during the 2nd quarter worth about $32,000. Finally, Root Financial Partners LLC increased its position in shares of Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 123 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Citigroup increased their target price on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Barclays assumed coverage on shares of Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 target price for the company. Freedom Capital upgraded shares of Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Finally, Argus upgraded shares of Biogen to a “hold” rating in a research report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $217.26.

Biogen Stock Performance

Shares of Biogen stock opened at $200.05 on Friday. The firm has a fifty day moving average of $188.73 and a two-hundred day moving average of $184.31. The stock has a market capitalization of $29.54 billion, a price-to-earnings ratio of 21.46 and a beta of 0.20. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts predict that Biogen Inc. will post 14.18 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.